European Society of Anaesthesiology and Intensive Care

European Society of Anaesthesiology and Intensive Care (ESAIC) Recommends Noninvasive, Continuous Hemoglobin Monitoring

Retrieved on: 
Wednesday, March 15, 2023
Medical Devices, Surgery, Hospitals, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Oncology, Multimedia, Research, Dräger, Blood, Patient safety, Mortality, European Society of Anaesthesiology and Intensive Care, Light, MASI, Workload, Bleeding, Anesthesiology, Organization, Systematic review, Patient, Judgement, Anemia, European Society for Medical Oncology, Intensive care medicine, Philips, GE, Medical imaging, Medical device, Nursing, HB

Masimo (NASDAQ: MASI) today announced that updated guidelines published by the European Society of Anaesthesiology and Intensive Care (ESAIC) highlight the value of noninvasive, continuous hemoglobin (Hb) monitoring in helping clinicians manage perioperative bleeding.

Key Points: 
  • Masimo (NASDAQ: MASI) today announced that updated guidelines published by the European Society of Anaesthesiology and Intensive Care (ESAIC) highlight the value of noninvasive, continuous hemoglobin (Hb) monitoring in helping clinicians manage perioperative bleeding.
  • Utilizing multiple wavelengths of light, SpHb provides real-time, continuous visibility to changes in the hemoglobin trend between invasive blood samples.
  • Noninvasive hemoglobin monitoring has an important role throughout the perioperative period and in acute care, as it can provide trend data for more informed decision making.
  • Clinical decisions regarding red blood cell transfusions should be based on the clinician’s judgment considering, among other factors, patient condition, continuous SpHb monitoring, and laboratory diagnostic tests using blood samples.

New European “Guidelines for the Management of Severe Perioperative Bleeding” Consider Hemoadsorption for the First-Time

Retrieved on: 
Tuesday, March 7, 2023
European Society for Medical Oncology, Anemia, European Journal, Ticagrelor, Professional corporation, European Society of Anaesthesiology and Intensive Care, Task force, U.S. FDA, Hospital, Intensive care medicine, FDA, Cytosorbents Corporation, AstraZeneca, European Journal of Anaesthesiology, Bleeding, Intra, Health Canada, Rivaroxaban, European, Randomized controlled trial, Patient, Cytokine adsorbing column, Risk, Medical device, Bayer

PRINCETON, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that hemoadsorption of antithrombotic drugs in cardiothoracic surgery has made its way into the new “2022 Guidelines for the Management of Severe Perioperative Bleeding” by the European Society of Anaesthesiology and Intensive Care ( ESAIC ) and was published in the European Journal of Anaesthesiology last week.

Key Points: 
  • PRINCETON, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that hemoadsorption of antithrombotic drugs in cardiothoracic surgery has made its way into the new “2022 Guidelines for the Management of Severe Perioperative Bleeding” by the European Society of Anaesthesiology and Intensive Care ( ESAIC ) and was published in the European Journal of Anaesthesiology last week.
  • The aim of this second update to the guidelines previously published in 2017, was to provide an evidence-based set of recommendations to aid in the clinical management of patients at risk of surgical bleeding in a variety of clinical situations.
  • The ESAIC Guideline Committee and Task Force worked with 20 expert affiliate co-authors to conduct a systematic literature search from 2015 – 2021, ultimately identifying approximately 138,000 articles that were assessed and, where appropriate, were used as new evidence to support the new guidelines.
  • CytoSorb® is already CE mark approved in the European Union to remove the blood thinners Brilinta®/Brilique® (ticagrelor, AstraZeneca) and Xarelto® (rivaroxaban, Bayer, Janssen/Johnson & Johnson) during cardiothoracic surgery, and is being used for these indications in many hospitals throughout the world.

Flat Medical Enters the Vascular Access Medtech Domain with its Newly Acquired MDR Certification and New Medical Advisor

Retrieved on: 
Tuesday, July 12, 2022
Clinical professor, Emergency medicine, Safety, Intensive care medicine, Notified body, MDR, Medical device regulation, European Society of Anaesthesiology and Intensive Care, Medtech, CVC, Certification, Patient, BSI, Physician, Congress, Central, Mayo Clinic, Association, Anesthesia, AVA, Medical device

"This is a super exciting achievement for our team with significantly meaningful value," said Shao-Wei Tseng, the Chief Regulatory Officer of Flat Medical.

Key Points: 
  • "This is a super exciting achievement for our team with significantly meaningful value," said Shao-Wei Tseng, the Chief Regulatory Officer of Flat Medical.
  • "As the first Taiwanese Medtech company awarded MDR certification from the BSI, we feel honored to be certified to supply our innovative solution to improve the safety and quality of central venous catheterization procedures."
  • Flat Medical is now organizing a product launch with its local partners in the U.S. and Europe.
  • Flat Medical is a MedTech company that focuses on safety solutions for clinical procedures.

Painful Sore Throats Meet Their Match - Mucinex® Introduces Mucinex InstaSoothe, a New Line of Lozenges and Spray to Help Fight Against Sore Throat Pain and Irritation

Retrieved on: 
Monday, November 1, 2021
Honey, Public opinion, Head, Enfamil, MD, Dextromethorphan, Guaifenesin, ENT, Sore throat, Cough, Association, CA, Ibuprofen brand names, Amazon, Partnership, Target, Marketing, Veet, American Association for Public Opinion Research, AAPOR, Otorhinolaryngology, Reckitt, Echinacea, Fever, Menthol, RB, Migraine, Air Wick, OnePoll, Walmart, OTC, Multimedia, Irritation, ESOMAR, Market Research Society, Benzocaine, Pain, Research, JAMA Otolaryngology–Head & Neck Surgery, American Association, Clearasil, CVS, Numb, Lysol, European Society of Anaesthesiology and Intensive Care, Opinion, Mouth, Glass wool, Grocery store

Mucinex InstaSoothe Sore Throat + Cough Relief Lozenges: Clinically proven to numb pain fast, Mucinex InstaSoothe Sore Throat + Cough Relief Lozengesare made with active ingredients Hexylresorcinol and Dextromethorphan HBr to quiet cough, provide cooling comfort, and relieve sore throat pain for up to two hours.

Key Points: 
  • Mucinex InstaSoothe Sore Throat + Cough Relief Lozenges: Clinically proven to numb pain fast, Mucinex InstaSoothe Sore Throat + Cough Relief Lozengesare made with active ingredients Hexylresorcinol and Dextromethorphan HBr to quiet cough, provide cooling comfort, and relieve sore throat pain for up to two hours.
  • Mucinex InstaSoothe Sore Throat + Pain Relief Spray:With two powerful pain relievers, Benzocaine and Menthol, the Mucinex InstaSoothe Sore Throat + Pain Relief Spray temporarily relieves pain to soothe the throat.
  • "What separates Mucinex InstaSoothe lozenges from others is that they're clinically proven to numb sore throat pain fast."
  • For those needing relief from a sore throat and cough, the Mucinex InstaSoothe Sore Throat + Cough Relief Lozenges also contain the active ingredient Dextromethorphan HBr to provide cough suppression."